Citrullination, NETs and Rheumatoid Arthritis
The enzyme that makes the weapon is the enzyme that makes the target. A neutrophil extrudes its own chromatin as a NET to trap bacteria, and the step that makes that physically possible is PAD4 converting arginine to citrulline on histones \u2014 which removes positive charge, loosens the histone grip on DNA and lets the chromatin decondense. Citrullinated histone is also the dominant autoantigen of rheumatoid arthritis. ACPA, the autoantibody that defines seropositive disease, is raised against precisely the material the NET is made of; the immune complexes it forms engage Fc receptors on neutrophils; and those neutrophils make more NETs. This map follows that loop, and the reagent question it raises: the loop can be interrupted at almost every point except the citrullination itself. Click any protein for the matching Assay Genie In Vivo antibody or ELISA kit.
The modification is the mechanism and the modification is the antigen. PAD4 citrullinates histone arginines, which removes positive charge and loosens the histone\u2013DNA grip enough for chromatin to decondense and be extruded. Neutrophil elastase and myeloperoxidase translocate to the nucleus and assist; gasdermin D pores permeabilise the membrane for the lytic form of release. What comes out is a mesh of DNA carrying citrullinated histone H3, elastase and MPO \u2014 an efficient antimicrobial structure, and simultaneously a display of the principal autoantigens of rheumatoid arthritis and ANCA vasculitis. There is no version of NET formation that does not generate citrullinated protein, because the citrullination is what makes the extrusion possible.
The loop is why seropositive disease sustains itself. ACPA forms immune complexes against citrullinated chromatin. Those complexes engage CD16 and Fc\u03b3RII/III on neutrophils, and engaged neutrophils release more NETs, which supply more citrullinated antigen. That is a closed positive-feedback loop with no external input required once it has started, which is the most economical account of why ACPA positivity predicts erosive disease and why ACPA can be detected years before clinical onset. It also explains why the loop, rather than any single node in it, is the sensible place to intervene.
Gr-1 is the reagent problem underneath a large part of this literature. Clone RB6-8C5 recognises both Ly-6G and Ly-6C, so it depletes inflammatory monocytes alongside neutrophils. A substantial body of work attributing arthritis phenotypes to neutrophils rests on it. Clone 1A8 is Ly-6G-specific and is what a neutrophil depletion experiment should use; HK1.4 covers Ly-6C separately; CSF-1R removes the mononuclear compartment and CD8 the lymphocyte arm. All are functional grade here, so the full control panel is available rather than a single antibody standing in for a conclusion \u2014 which matters disproportionately in a disease model where several cell types arrive at once.
The In Vivo tie-in, and where the map is thin. 24 of the 37 nodes carry a functional-grade antibody, and they cover every step of the loop except the citrullination. Critically, the Fc receptors that close it are among them: human CD16 (clone 3G8) and Fc\u03b3RII/III, so the immune-complex arm can be interrupted directly. Recruitment and arrest are covered end to end \u2014 GM-CSF, CD11a (FD441.8), CD11b, CD11c, CD18, CD62L in both species, CD49d and ICAM-1 in both species \u2014 alongside TNF, IL-1\u03b2 with IL-1R1, CD68, IL-10, TGF-\u03b2 and the VivoGenie anti-IL-17A, which is the ixekizumab sequence in functional grade. Stated plainly, the citrullination step is a read-out and not a target: PAD4, MPO, elastase, MMP-9, NGAL, CXCL8, CXCR2 and ACPA are ELISA only; citrullinated histone H3 and gasdermin D are research grade; and C5, C5aR1 and IL-23 are biosimilar. The productive design follows from that asymmetry \u2014 interrupt the complexes, the recruitment or the amplifier, and measure citrullinated H3, MPO\u2013DNA complexes and NGAL. Two cautions worth carrying: the Fc\u03b3RII/III antibody blocks activating and inhibitory receptors together, making it a blockade tool rather than a dissection tool, and mice have no direct CXCL8 orthologue, so the human chemokine arm does not carry across into a mouse arthritis model. For research use only; not for use in diagnostic or therapeutic procedures.
Every protein node links to a product — ELISA kit, In Vivo antibody or research antibody.